Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLS-3000
- Development stage
- Preclinical
- Lead developer
- GeneOne Life Science
- Modality
- Small Molecules
01
Overview
GLS-3000 is a preclinical-stage small molecule therapeutic candidate developed by GeneOne Life Science for the treatment of COVID-19. It functions as a SARS-CoV-2 spike (S) protein inhibitor, designed to block the interaction between the viral spike protein and host cell receptors, thereby preventing viral entry and infection. Unlike many spike-targeting agents that are monoclonal antibodies, GLS-3000 represents a small molecule approach to inhibiting the SARS-CoV-2 virus.
- Other names
- GLS-3000GLS3000GLS 3000
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on GLS-3000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLS-3000.